When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia

Vox Sanguinis

Volumn 108, Issue 1, 2015, Pages 1-10

  Taher, A T ^a   Radwan, A ^a   Viprakasit, V ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Haemoglobin E thalassaemia; Haemoglobin H disease; Iron chelation; Non transfusion dependent thalassaemia; Red cell transfusion; thalassaemia intermedia

Indexed keywords

HEMOGLOBIN;

ACUTE HEMOLYSIS; ADRENAL INSUFFICIENCY; ALLOIMMUNIZATION; ALPHA THALASSEMIA; ANEMIA; AWARENESS; BETA THALASSAEMIA INTERMEDIA; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL FEATURE; DISEASE SEVERITY; ERYTHROCYTE DISORDER; FOLIC ACID DEFICIENCY; GALLSTONE; HEART RIGHT VENTRICLE FAILURE; HEMOGLOBIN E-BETA THALASSEMIA; HEMOLYSIS; HUMAN; INEFFECTIVE ERYTHROPOIESIS; INTESTINE ABSORPTION; IRON ABSORPTION; IRON CHELATION; IRON OVERLOAD; LEG ULCER; LIVER CELL CARCINOMA; NON TRANSFUSION DEPENDENT THALASSAEMIA; OSTEOPENIA; OSTEOPOROSIS; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; REVIEW; THALASSEMIA; THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; ADVERSE EFFECTS; BLOOD; CHELATION THERAPY;

BLOOD TRANSFUSION; CHELATION THERAPY; HUMANS; THALASSEMIA;

EID: 84919674531     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12201     Document Type: Review

References (95)

1. Fucharoen S, Winichagoon P: Hemoglobinopathies in Southeast Asia. Hemoglobin 1987; 11:65-88
2. Fucharoen S, Ketvichit P, Pootrakul P, et al.: Clinical manifestation of beta-thalassemia/hemoglobin E disease. J Pediatr Hematol Oncol 2000; 22:552-557
3. Fucharoen S, Winichagoon P: New updating into hemoglobinopathies. Int J Lab Hematol 2012; doi: 10.1111/j.1751-553X.2012.01446.x [Epub ahead of print].
4. Olivieri NF: The beta-thalassemias. N Engl J Med 1999; 341:99-109
5. Sripichai O, Makarasara W, Munkongdee T, et al.: A scoring system for the classification of beta-thalassemia/Hb E disease severity. Am J Hematol 2008; 83:482-484
6. Galanello R, Origa R: Beta-thalassemia. Orphanet J Rare Dis 2010; 5:11
7. Modell B, Darlison M: Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86:480-487
8. Weatherall DJ: The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010; 115:4331-4336
9. Weatherall DJ, Clegg JB: The Thalassaemia Syndromes, 4th edn. Oxford, UK, Blackwell Science, 2001
10. Harteveld CL, Higgs DR: Alpha-thalassaemia. Orphanet J Rare Dis 2010; 5:13
11. Lal A, Goldrich ML, Haines DA, et al.: Heterogeneity of hemoglobin H disease in childhood. N Engl J Med 2011; 364:710-718
12. Vichinsky E: Hemoglobin e syndromes. Hematology Am Soc Hematol Educ Program 2007:79-83
13. Viprakasit V, Tanphaichitr VS, Pung-Amritt P, et al.: Clinical phenotypes and molecular characterization of Hb H-Pakse disease. Haematologica 2002; 87:117-125
14. Weatherall DJ: The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev 2012; 26(Suppl 1):S3-S6
15. Lorey F, Cunningham G, Vichinsky EP, et al.: Universal newborn screening for Hb H disease in California. Genet Test 2001; 5:93-100
16. Michlitsch J, Azimi M, Hoppe C, et al.: Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer 2009; 52:486-490
17. Sanpakit K, Viprakasit V: Variable genotype-phenotype correlations in patients with a rare non-deletional α-thalassemia; Hb Pak Num Po (HBA1:c.396_397insT). J Pediatr Hematol Oncol 2014; 36:e185-e189.
18. Viprakasit V: Alpha thalassemia syndromes: from clinical and molecular diagnosis to bedside management. EHA 18 Education Book 2013
19. Viprakasit V, Ekwattanakit S, Chalaow N, et al.: Clinical presentation and molecular identification of four uncommon α-globin variants in Thailand: initiation codon mutation of α2-globin gene (HBA2:c.1delA), donor splice site mutation of α1-globin gene (IVSI-1, HBA1:c.95+1G>A), Hemoglobin Queens Park/Chao Pra Ya (HBA1:c.98T>A) and Hemoglobin Westmead (HBA2:c.369C>G). Acta Haematol 2013; 131:88-94
20. Weatherall DJ, Clegg JB: Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 2001; 79:704-712
21. Laosombat V, Viprakasit V, Chotsampancharoen T, et al.: Clinical features and molecular analysis in Thai patients with HbH disease. Ann Hematol 2009; 88:1185-1192
22. Taher AT, Musallam KM, Cappellini MD, et al.: Optimal management of beta thalassaemia intermedia. Br J Haematol 2011; 152:512-523
23. Taher AT, Musallam KM, Karimi M, et al.: Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010; 115:1886-1892
24. Taher AT, Musallam KM, Karimi M, et al.: Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost 2010; 8:2152-2158
25. Taher AT, Musallam KM, Cappellini MD: Thalassaemia intermedia: an update. Mediterr J Hematol Infect Dis 2009; 1:e2009004
26. Musallam KM, Khoury B, Abi-Habib R, et al.: Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. Eur J Haematol 2011; 87:73-79
27. Taher AT, Musallam KM, Karimi M, et al.: Contemporary approaches to treatment of beta-thalassemia intermedia. Blood Rev 2012; 26(Suppl. 1):S24-S27
28. Taher AT, Cappellini MD, Musallam KM: Recent advances and treatment challenges in patients with non-transfusion-dependent thalassemia. Blood Rev 2012; 26(Suppl. 1):S1-S2
29. Cappellini MD, Cohen AR, Eleftheriou A, et al.: Guidelines for the Clinical Management of Thalassaemia, 2nd edn revised. Nicosia, Cyprus, Thalassaemia International Federation, 2008
30. Allen A, Fisher C, Premawardhena A, et al.: Adaptation to anemia in hemoglobin E-ss thalassemia. Blood 2010; 116:5368-5370
31. O'Donnell A, Premawardhena A, Arambepola M, et al.: Age-related changes in adaptation to severe anemia in childhood in developing countries. Proc Natl Acad Sci USA 2007; 104:9440-9444
32. Musallam KM, Taher AT, Rachmilewitz EA: Beta-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med 2012; 2:a013482
33. Premawardhena A, Fisher CA, Olivieri NF, et al.: Haemoglobin E beta thalassaemia in Sri Lanka. Lancet 2005; 366:1467-1470
34. Viprakasit V, Tanphaichitr VS, Chinchang W, et al.: Evaluation of alpha hemoglobin stabilizing protein (AHSP) as a genetic modifier in patients with beta thalassemia. Blood 2004; 103:3296-3299
35. Taher A, Vichinsky E, Musallam KM, et al.: Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT). TIF Publication No. 19. Nicosia, Cyprus, Thalassaemia International Federation, 2013
36. Eder AF, Chambers LA: Noninfectious complications of blood transfusion. Arch Pathol Lab Med 2007; 131:708-718
37. Rivella S: The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Rev 2012; 26(Suppl. 1):S12-S15
38. Musallam KM, Rivella S, Vichinsky E, et al.: Non-transfusion-dependent thalassemias. Haematologica 2013; 98:833-844
39. Haidar R, Mhaidli H, Taher AT: Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J 2010; 19:871-878
40. Cazzola M, Pootrakul P, Huebers HA, et al.: Erythroid marrow function in anemic patients. Blood 1987; 69:296-301
41. Cazzola M, Finch CA: Evaluation of erythroid marrow function in anemic patients. Haematologica 1987; 72:195-200
42. Cazzola M, De Stefano P, Ponchio L, et al.: Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol 1995; 89:473-478
43. Musallam KM, Nasreddine W, Beydoun A, et al.: Brain positron emission tomography in splenectomized adults with beta-thalassemia intermedia: uncovering yet another covert abnormality. Ann Hematol 2012; 91:235-241
44. Taher A, Isma'eel H, Mehio G, et al.: Prevalence of thromboembolic events among 8, 860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006; 96:488-491
45. Vichinsky E: Advances in the treatment of alpha-thalassemia. Blood Rev 2012; 26(Suppl 1):S31-S34
46. Anuwatanakulchai M, Pootrakul P, Thuvasethakul P, et al.: Non-transferrin plasma iron in beta-thalassaemia/Hb E and haemoglobin H diseases. Scand J Haematol 1984; 32:153-158
47. Pootrakul P, Rugkiatsakul R, Wasi P: Increased transferrin iron saturation in splenectomized thalassaemic patients. Br J Haematol 1980; 46:143-145
48. Pootrakul P, Vongsmasa V, La-ongpanich P, et al.: Serum ferritin levels in thalassemias and the effect of splenectomy. Acta Haematol 1981; 66:244-250
49. Taher A, Hershko C, Cappellini MD: Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br J Haematol 2009; 147:634-640
50. Musallam KM, Cappellini MD, Wood JC, et al.: Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev 2012; 26(Suppl 1):S16-S19
51. Musallam KM, Cappellini MD, Wood JC, et al.: Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica 2011; 96:1605-1612
52. Restivo Pantalone G, Renda D, Valenza F, et al.: Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience. Br J Haematol 2010; 150:245-247
53. Cappellini MD, Musallam KM, Poggiali E, et al.: Hypercoagulability in non-transfusion-dependent thalassemia. Blood Rev 2012; 26(Suppl. 1):S20-S23
54. Taher AT, Musallam KM, Nasreddine W, et al.: Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost 2010; 8:54-59
55. Chen S, Eldor A, Barshtein G, et al.: Enhanced aggregability of red blood cells of beta-thalassemia major patients. Am J Physiol 1996; 270:H1951-H1956
56. Sonakul D, Pacharee P, Laohapand T, et al.: Pulmonary artery obstruction in thalassaemia. Southeast Asian J Trop Med Public Health 1980; 11:516-523
57. Sonakul D, Suwanagool P, Sirivaidyapong P, et al.: Distribution of pulmonary thromboembolic lesions in thalassemic patients. Birth Defects Orig Artic Ser 1987; 23:375-384
58. Sonakul D, Fucharoen S: Pulmonary thromboembolism in thalassemic patients. Southeast Asian J Trop Med Public Health 1992; 23(Suppl 2):25-28
59. Aessopos A, Farmakis D, Karagiorga M, et al.: Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001; 97:3411-3416
60. Teawtrakul N, Ungprasert P, Pussadhamma B, et al.: Effect of genotype on pulmonary hypertension in patients with thalassemia. Blood 2013; 122:abst 3456
61. Chuncharunee S, Atichartakarn V, Udomsubpayakul U, et al.: Features associated with pulmonary hypertension in splenectomized patients with hemoglobin E/β-thalassemia disease. Blood 2013; 122:abst 3457
62. Chueamuangphan N, Wongtheptien W, Nawarawong W, et al.: Clinical indicators for pulmonary arterial hypertension in thalassemia. J Med Assoc Thai 2012; 95:16-21
63. Yin X, Zhang X, Wu Z, et al.: Pulmonary hypertension risk in patients with haemoglobin H disease: low incidence and absence of correlation with splenectomy. Acta Haematol 2013; 130:153-159
64. Isma'eel H, Chafic AH, Rassi FE, et al.: Relation between iron-overload indices, cardiac echo-Doppler, and biochemical markers in thalassemia intermedia. Am J Cardiol 2008; 102:363-367
65. Morris CR, Vichinsky EP: Pulmonary hypertension in thalassemia. Ann N Y Acad Sci 2010; 1202:205-213
66. Phrommintikul A, Sukonthasarn A, Kanjanavanit R, et al.: Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia. Heart 2006; 92:1467-1472
67. Singer ST, Kuypers FA, Styles L, et al.: Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol 2006; 81:670-675
68. Aessopos A, Stamatelos G, Skoumas V, et al.: Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia. Chest 1995; 107:50-53
69. Gibbs JSR, Higenbottam TW: Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001; 86:i1-i13
70. Claster S, Hammer M, Hagar W, et al.: Treatment of pulmonary hypertension in sickle cell disease with transfusion. Blood 1999; 94(Suppl 1):abst 420a
71. Atichartakarn V, Chuncharunee S, Chandanamattha P, et al.: Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/beta-thalassemia patient. Blood 2004; 103:2844-2846
72. Taher AT, Musallam KM, El-Beshlawy A, et al.: Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol 2010; 150:486-489
73. Levin C, Koren A: Healing of refractory leg ulcer in a patient with thalassemia intermedia and hypercoagulability after 14 years of unresponsive therapy. Isr Med Assoc J 2011; 13:316-318
74. Phadke SR, Agarwal S: Phenotype score to grade the severity of thalassemia intermedia. Indian J Pediatr 2003; 70:477-481
75. Taher A, Isma'eel H, Cappellini MD: Thalassemia intermedia: revisited. Blood Cells Mol Dis 2006; 37:12-20
76. Viprakasit V, Tanphaichitr VS, Mahasandana C, et al.: Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens. J Med Assoc Thai 2001; 84:929-941
77. Nakavachara P, Viprakasit V: Adrenal insufficiency is prevalent in HbE/beta-thalassaemia paediatric patients irrespective of their clinical severity and transfusion requirement. Clin Endocrinol (Oxf) 2013; 79:776-783.
78. Nakavachara P, Viprakasit V: Children with hemoglobin E/beta-thalassemia have a high risk of being vitamin D deficient even if they get abundant sun exposure: a study from Thailand. Pediatr Blood Cancer 2013; 60:1683-1688
79. Napoli N, Carmina E, Bucchieri S, et al.: Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone 2006; 38:888-892
80. Viprakasit V, Sawathiparnich P, Sangpraypanm T, et al.: Osteopenia is commonly present in prepubertal children with severe HbE/βthalassemia despite adequate transfusion and iron chelation therapy. Blood 2007; 110:abst 3830
81. Spanos T, Karageorga M, Ladis V, et al.: Red cell alloantibodies in patients with thalassemia. Vox Sang 1990; 58:50-55
82. Sirchia G, Zanella A, Parravicini A, et al.: Red cell alloantibodies in thalassemia major. Results of an Italian cooperative study. Transfusion 1985; 25:110-112
83. Singer ST, Wu V, Mignacca R, et al.: Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly asian descent. Blood 2000; 96:3369-3373
84. Chou ST, Liem RI, Thompson AA: Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol 2012; 159:394-404
85. Kosaryan M, Mahdavi MR, Roshan P, et al.: Prevalence of alloimmunisation in patients with beta thalassaemia major. Blood Transfus 2012; 10:396-397
86. Vichinsky E, Neumayr L, Trimble S, et al.: Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention. Transfusion 2014; 54:972-981
87. Thompson AA, Cunningham MJ, Singer ST, et al.: Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Haematol 2011; 153:121-128
88. Al-Riyami AZ, Al-Mahrooqi S, Al-Hinai S, et al.: Transfusion therapy and alloimmunization in thalassemia intermedia: a 10 year experience at a tertiary care university hospital. Transfus Apher Sci 2014, http://dx.doi.org/10.1016/j.transci.2014.04.009 (Epub ahead of print)
89. Taher A, El RF, Isma'eel H, et al.: Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 2008; 93:1584-1586
90. Taher AT, Musallam KM, Wood JC, et al.: Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am J Hematol 2010; 85:288-290
91. Taher AT, Viprakasit V, Musallam KM, et al.: Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol 2013; 88:409-415
92. Tony S, Daar S, Elshinawy M, et al.: T2* MRI in regularly transfused children with thalassemia intermedia: serum ferritin does not reflect liver iron stores. Pediatr Hematol Oncol 2012; 29:579-584
93. Taher AT, Porter J, Viprakasit V, et al.: Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 2012; 120:970-977
94. Cohen AR, Galanello R, Pennell DJ, et al.: Thalassemia. Hematology Am Soc Hematol Educ Program 2004:14-34
95. Origa R, Sollaino MC, Giagu N, et al.: Clinical and molecular analysis of haemoglobin H disease in Sardinia: haematological, obstetric and cardiac aspects in patients with different genotypes. Br J Haematol 2007; 136:326-332